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Abstract: Macular edema (ME) is one of the eventual outcomes of various intraocular and 
systemic pathologies. The pathogenesis for ME is not yet entirely understood; however, 
some of the common risk factors for its development have been identified. While this 
investigation will not discuss the numerous etiologies of ME in detail, it appraises the two 
most widely studied delivery modalities of intraocular corticosteroids in the treatment of 
ME—intravitreal injection (IVI) and sub-Tenon’s infusion (STI). A thorough review of the 
medical literature was conducted to identify the efficacy and safety of IVI and STI, 
specifically for the administration of triamcinolone acetonide (TA), in the setting of ME in 
an attempt to elucidate a preferred steroid delivery modality for treatment of ME.  
Keywords: macular edema; intravitreal injection; sub-Tenon’s injection; corticosteroids; 
triamcinolone 
 
1. Introduction  
Macular edema (ME) is one potential outcome of various intraocular and systemic pathologies, such 
as diabetic retinopathy, retinal vein occlusion, and operative complications. Though the pathogenesis 
for ME is not yet entirely understood and highly dependent on the etiology of ocular injury, common 
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risk factors for its development have been identified, including fluctuations in glucose level and retinal 
hypoxia, as seen in diabetic macular edema. Such insults are thought to cause a hypoxia-induced 
upregulation of VEGF and recruitment of inflammatory mediators to the retina, which allows fluid to 
collect behind the macula of the eye and leads to central visual distortion and potential vision loss if 
left untreated. 
Given the variable nature of this process, current treatment and management of ME is a significant 
challenge to any practicing ophthalmologist. In general, the main goals of ME therapy are to:  
(1) reduce inflammation; (2) reduce VEGF production; and (3) reduce blood-retinal barrier (BRB) 
breakdown. Decreasing the inflammatory response and restoring tight junctions are key elements in 
restoring the healthy anatomy of the macula and vision [1]. This is most apparent in the cases of 
chronic and persistent ME, in which stepwise approaches to care must be considered. Though various 
treatment options are now available to achieve these goals of therapy, the use of corticosteroids has 
continued to be a mainstay in the management of ME. 
Treatment with corticosteroids has been shown to be effective in reducing ME associated with 
diabetic retinopathy, vein occlusions, and other pathologies by inhibiting the formation of 
prostaglandins, which are potent regulators of inflammatory mediation. Additionally, corticosteroids 
contain certain anti-angiogenic properties that provide further benefit to patients suffering from ME [2]. 
Various routes of corticosteroid administration exist in the treatment of ME, including topical 
application, oral intake, and intraocular injection or infusion of steroids. However, oftentimes in 
clinical practice, intraocular injections and infusions have proven to be more efficacious than topical or 
systemic steroids in the management of certain ocular pathologies, of which ME is included. This 
difference in efficacy is attributed to the fact that corticosteroids are more likely to achieve therapeutic 
concentrations and their effects are sustainable for a greater duration of time when administered 
intraocularly [3]. Therefore, given the widespread use of these injections and infusions in patients with 
ME, we will conduct a thorough review of the two most extensively studied intraocular steroid delivery 
modalities—intravitreal injection and sub-Tenon’s infusions—and appraise the efficacy and safety of 
each in an attempt to better understand factors affecting the treatment of ME and reveal a preferred 
steroid delivery method in the management of this process. 
2. Barriers Affecting Drug Delivery and Metabolism 
Before discussing the different methods of intraocular steroid delivery, it is important to understand 
the three types of barriers that exist within the eye: static, dynamic, and metabolic. These barriers can 
affect the physical delivery of a drug, the efficacy of a drug once inside the eye, and its metabolism 
and clearance. 
2.1. Static Barriers  
Static barriers are those that provide a physical impediment to foreign substances. The static 
barriers found within the eye are composed of different segments—the cornea, sclera, retina, and the  
blood-retina barriers. Ex-vivo studies have been conducted extensively with respect to factors pertinent 
to the permeability of scleral tissue. Such influencing factors are molecular weight/molecular radius, 
lipophilicty, and charge. Permeability of scleral tissue for large and small molecules is low and high, 
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respectively [4–7]. Interestingly, molecular radius has a more profound impact on permeability than 
molecular weight. In studies conducted on rabbits, globular proteins of the same molecular weight as 
linear dextrans proved to be more permeable [8]. Further research in this area has proven that as 
molecular radius increases there is an exponential decrease in permeability. These effects could be 
explained by the structure of the sclera. Scleral tissue is composed of collagen and elastin fibers 
arranged in a matrix array. This matrix allows for the presence of pores that may be of variable size in 
regional areas of the sclera (i.e., looser fiber matrix in the posterior sclera compared to anterior) [9,10]. 
Permeability of scleral tissue decreases as the lipophilicty increases which is thought to be the result of 
proteoglycans found in the tissue. These proteoglycans allow easier passage of hydrophilic compounds 
when compared to lipophilic compounds [11]. Another variable to take into account would be with 
regards to charged particles, where negatively charged particles are more permeable than positively 
charged particles [12,13]. Positively charged particles are thought to form bonds with the negatively 
charged proteoglycans found in scleral tissue [14].  
Studies involving Bruch’s membrane-choroid complex (BC complex) and retinal pigment epithelium 
(RPE) have not been as extensively investigated as the sclera [15]. Over the course of many different 
studies the conclusions with respect to changes in permeability have been identified. The BC complex 
behaves much like the sclera in regards to molecular radius, lipophilicity, and charged  
molecules [12,16]. RPE behaves nearly identical to sclera in reference to molecular radius. However, 
RPE behaves differently with regards to lipophilicty, where permeability increases as solute lipid 
solubility increases [17]. 
2.2. Dynamic Barriers 
While static barriers and their permeability have been studied primarily ex-vivo, dynamic barriers 
can only be studied in-vivo. The properties that constitute dynamic barriers include: clearance of drugs 
through blood vessels and lymphatic flow, bulk fluid flow, and active transport within the RPE. Two 
experiments, done in parallel with rabbits, were conducted to determine which mechanism of clearance 
most extensively limits drug delivery via a transscleral modality. They first utilized cryotherapy to 
effectively destroy RPE and choroidal capillaries. The authors report that there was very little change 
in penetration of STI-TA post cryotherapy. In the second experiment a conjunctival/episcleral 
“window” was incised thus eliminating the blood vessels and lymphatics within these tissues. After 
formation of the window, placement of STI-TA was performed and significant penetration of the drug 
was observed. These results indicate that choroidal elimination of transscleral delivered drugs is minimal 
when compared to conjunctival/episcleral clearance [6,18,19].  
Clearance studies have given rise to a better understanding of dynamic barriers while other areas 
such as bulk fluid flow, in the form of uveoscleral outflow, are still limited. While an unorthodox 
pathway for aqueous humor fluid flow in the eye, uveoscleral outflow may have a profound effect on 
drug delivery by trapping therapeutic agents in its convective flow of aqueous humor [20]. In addition, 
RPE transporters may have the added effect of eliminating therapeutic agents lowering drug 
bioavailablity. The presence of efflux pumps in the form of P-glycoprotien (P-gp) and multidrug-
resistance associated proteins (MRPs) may direct drugs away from the retina and promote their 
clearance via the choroidal circulation [6].  
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2.3. Metabolic Barriers 
Inherent metabolic enzyme systems are responsible for the eye’s protection against foreign 
molecules. While the primary sites of production of these enzymes have been examined, the study of 
these enzymes and their effects on pharmacokinetics of therapeutic agents is limited [21]. The two 
most widely studied metabolic enzymes within the eye are the cytochrome P-450 enzyme and 
lysosomal enzymes [6]. These enzymes may have a very important role in ocular drug delivery; 
however, more research is needed to understand their function in order to improve results.  
3. Intravitreal Injection of Corticosteroids to the Posterior Pole 
The currently utilized practice of intravitreal injection (IVI) arose out of blood-ocular barrier 
research in the 1970s. This investigation initiated the concept of delivering corticosteroids to the vitreal 
cavity as a modality for treating intraocular inflammation [2,22]. Corticosteroids have been utilized for 
their anti-inflammatory properties by hindering mediator response and reducing cytokine production. 
However, the angiostatic and antipermeability characteristics of corticosteroids are the focus of more 
contemporary research studies for treatment of posterior segment diseases, including ME [23].  
IVI is usually an in-office procedure performed using topical anesthesia. A survey of retinal 
physicians from 2006 reports that a majority of practitioners use topical anesthesia (66.6%) in contrast 
to subconjunctival anesthesia (33.3%) during this procedure [24]. Also, when performing IVI, proper 
aseptic technique should be executed along with the application of povidine-iodine solutions to decrease 
the risk for contamination by normal conjunctival flora. IVI technique employs the use of a compass to 
measure 3 to 4mm posterior to the limbus in order to identify the region of the pars plana. Through this 
region using a 30 to 32 gauge needle, therapeutic agents can be safely introduced into the vitreal 
chamber. The agent for IVI is normally injected slowly in the infero-temporal quadrant in order to 
prevent interference with the patient’s visual field [2]. (See Figure 1) 
The benefits of IVI consist of sustained and sufficient release of the drug to the posterior segment of 
the eye while diminishing potential side effects of corticosteroids by circumventing the blood-ocular 
barrier. This drug delivery modality may also reduce the issue of noncompliance in patients [23]. 
However, there are also complications that have been associated with this procedure; a known 
consequence of electing to perform IVI is the patient’s associated risk of developing endophthalmitis. 
A report from the DRCRnet and SCORE trials provided a detailed procedure for the prevention of the 
development of endophthalmitis following IVI without the use of prescribing prior antibiotics. They 
reported an incidence of endophthalmitis of 0.05% (95% confidence interval, 0.001%–0.277%), with 
total IVI injections of n = 2009 [25].  
3.1. Triamcinolone Acetonide 
Triamcinolone acetonide (TA), specifically intravitreally-injected TA (IV-TA), has been extensively 
studied over the last decade as it is a common corticosteroid used in IVI for the treatment of ME. 
Steroids are effective in the treatment of intraocular edema because inflammation often accompanies 
and incites abnormal growth of intraocular cells. Furthermore, steroids help protect from fluid 
accumulation in the macula region caused by capillary defects in the blood-retina barrier. TA is one of 
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the few corticosteroids available in a crystalline form, which allows for long-lasting concentrations in 
the vitreal chamber to be achieved without the addition of a vehicle to improve sustainability [3,26,27].  
3.2. Efficacy of IV-TA 
While variations in the primary outcome measurements of different clinical trials do exist with 
regard to treatment with intravitreal-TA (IV-TA), they ultimately point to a common assessment of its 
efficacy. Most outcomes were measured on basis of ≥5-letter increase in best-corrected visual acuity 
(BCVA) and changes in central macular thickness (CMT). A two-year, double-blinded and randomized 
clinical trial reported that with treatment of 0.1 mL TA (40 mg/mL [Kentacort 40 Bristol-Meyers 
Pharmaceuticals]), 19 of 34 IV-TA patients compared to 9 of 35 placebo patients saw an improvement 
of ≥5 letters (P = 0.006). In this same study, foveal thickness was reduced by up to 59 µm in the  
IV-TA group as compared to the placebo group [28]. Another clinical trial with nearly identical 
treatment protocol reported 18 of 33 IV-TA patients compared to 5 of 32 placebo patients saw an 
improvement of ≥5 letters (P < 0.001). Additionally, macular thickness was significantly reduced by at 
least 1 grade in 25 of 33 IV-TA patients versus 5 of 32 placebo patients (P < 0.0001) [29]. In a 2011 
study involving IV-TA and laser treatment, Gillies et al. reported that an improvement in BCVA of  
10 letters or more recorded in logarithm of the minimal angle of resolution (logMAR) units was found 
in 15 of 42 eyes treated with TA prior to laser treatment compared to 7 of 42 eyes with placebo over a 
24-month period (P = 0.047). Odds of improving by 10 letters or more were 2.79 times greater 
(Confidence interval 95%, 1.01–7.67) before laser therapy than in eyes treated exclusively with laser. 
While the IV-TA group showed a decrease in CMT, there was no statistically significant difference in 
CMT between the two groups [30].  
Whereas the aforementioned clinical trials used a dosage of 4 mg TA, other studies have investigated 
the differences in outcome seen when a range of doses is administered. Evaluating relatively small 
dosage amounts, one investigation reported the effects of IV-TA at 1 mg, 2 mg, and 4 mg, where  
n = 13, 17, 12 respectively, and in this study, all three dosage groups increased by 8 or 9 Early Treatment 
Diabetic Retinopathy Study (ETDRS) letters by 4 weeks. Interestingly, the 1 mg and 2 mg groups 
showed no remission at 24 weeks, while the 4 mg group showed a slight remission; however, in the 
course of the six-month study, there was no statistically significant difference among the three dosage 
groups. Baseline studies of CMT were similar among all three dosage groups, and all three improved 
by 4 weeks post-injection. Standardized-CMT (SCMT) was calculated for all three groups according to 
the equation outlined by Chan and Duker, 2005. The authors explained that the SMCT values for the  
4 mg dosage group were significantly worse than the 1 mg at all time points and worse than the 2 mg 
group at the 12- and 24-week follow-up; this lack of correlation between macular thickness and 
improvement in VA had been identified in previous studies [31,32]. In a study regarding the duration 
of effects of IV-TA dosages ranging from 20 to 25 mg, the authors reported an increase from a 
baseline of 0.93 ± 0.28 logMAR units to 0.79 ± 0.34 logMAR units at 1 month post-injection [26], and 
the gain in VA achieved a plateau-like effect between 1 to 7 months post-injection, returning to 
baseline between 8 and 9 months. However, it should be noted that there are several limitations 
described by the author of this study that hindered the gain of other significant conclusions on the 
effects of these dosages [30].  
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3.3. Drawbacks of IVTA 
Various studies highlighting the adverse effects associated with IV-TA use, including 
endophthalmitis, have also been performed. Maia M., et al. conducted a retrospective analysis in  
n = 471 patients receiving IVIs of Kenalog (KE) (Kenalog, Bristol-Myers Squibb, Princeton, NJ, USA) 
and preservative-free triamcinalone acetonide (PFTA) in which they reported that, in 646 IVIs of 
steroids, 12 eyes developed non-infectious endophthalmitis. Of these 12 eyes, five patients received 
injections of KE (n = 69, 7.3%) and seven received injections of PFTA (n = 577, 1.2%), and the results 
of this study were statistically significant (P = 0.005) for differences between the two preparations [33]. 
Additionally, a prior study by Nelson et al. documented similar findings as well as case reports of 
sterile endophthalmitis [34]. Interestingly, however, inflammation does not seem to be isolated solely 
to the intraocular use of TA; such events have been also documented following the intra-articular 
injection of TA as well [35].  
Other concerns regarding IV-TA include visual disturbances, elevation of intraocular pressure 
(IOP), and the risk of quickened cataract progression [3,36–39]. Patients reported, in a 2011 clinical 
study by Charalampidou et al., that they experienced flashing lights and floaters in their vision 
immediately following and up to 2 weeks post-procedure. These phenomena may be attributed to 
viscous deposits that are observed to accumulate on the surface of the eye and the transient increase in 
IOP immediately following injection, as elevated IOP after corticosteroid use has been a known 
complication for some time [36,40,41]. Jonas et al. investigated the implications of the IOP response to 
IV-TAs and found that IOP was increased significantly from 15.4 mmHg to a mean maximum of  
23.34 mmHg postoperatively (P < 0.001). Post-injection increases in IOP to greater than 21 mmHg 
were found to be statistically independent of sex, refractive error, presence of diabetes, and indication 
for the injection (age-related macular degeneration versus DME) [37]. Inatani et al. examined the 
various risk factors for the elevation of IOP in conjunction with IVI-TA use. The author’s used a Cox 
proportional hazards regression and found that IOP elevation after IVI-TA is independent of age and 
baseline IOP but found significant risk associated with higher dosage administration (P = 0.013) [42]. 
With respect to IV-TA and laser treatment, Gillies et al. explained that 27 of 42 IV-TA plus laser patients 
required management for elevated IOP as compared to 10 of 42 laser only eyes (P < 0.001) [30]. 
In addition to the laser treatment report, Gillies et al. have published an analysis of the effects of  
IV-TA on cataract development and progression. Over a three-year study, 2 of 25 sham injection 
patients together with 15 of 27 IV-TA patients underwent cataract surgery. All eyes showed ≥2 grade 
posterior subcapsular cataract (PSC) with significant visual impairment. They reported that in the 
initial steroid-treated group, cataract development took more than 12 months, and a further breakdown 
identified that 10 of 15 eyes that had three injections had progression of PSC, while only 5 of 12 eyes 
with less than three injections progressed (P = 0.009) [38]. The authors found reproducible results that 
demonstrated the association of PSC progression with increased IOP ≥ 5 mmHg from baseline at any 
time [39]. In a similar study by Gillies et al., cataract progression by 2 or more Age Related Eye 
Disease Study (AREDS) grades was found in 18 of 28 and 3 of 27 eyes that were phakic at baseline in 
the IV-TA plus laser group compared to the laser only group, respectively (P < 0.001) [30]. 
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4. Sub-Tenon’s Infusion of Corticosteroids to the Posterior Pole 
There are currently a few different methods of administering corticosteroids through sub-Tenon’s 
space discussed in the literature. Previously, it was common practice to perform sub-Tenon’s injections, 
using a sharp needle to inject drugs into the space beneath Tenon’s capsule. However, this carried the 
risk blepharoptosis and globe perforation [43]. Additionally, a bolus injection of drug may be less 
effective than a more gradual infusion as the sclera can become saturated, limiting the amount it is able 
to absorb at a given time [6,7]. More recently, most clinicians choosing the sub-Tenon’s route for 
steroid delivery employ a blunt, curved cannula for infusion rather than injection with a sharp needle. 
This long cannula is meant to reach behind the posterior globe to allow the steroid to infuse into the 
retrobulbar space, while reducing the risk of complications associated with needle use [43]. This method 
is often called trans-Tenon’s or sub-Tenon’s infusion (STI) (see Figure 1). Though this modality is 
used in clinical practice, it has been cited as a less efficient method of drug delivery to the retina than 
IVI due to the various barriers encountered between the sclera and the posterior pole. These barriers, as 
explained above, have been classified into three types: static, dynamic, and metabolic [6]. 
4.1. Efficacy of STI-TA 
A few studies have been conducted which evaluate the efficacy of STI corticosteroid delivery in the 
management of ME. Of note, one particular study reported results for the outcomes after STI steroid 
administration, which were comparable to those found in the aforementioned literature on IV-TA in 
eyes with ME. This study by Tomoyo K et al. examining the efficacy of trans-Tenon’s retrobulbar TA 
injections showed the final Snellen BCVA improved by two or more lines in 9 eyes and remained 
unchanged in 11 eyes. The authors indicate at the final follow up ME resolved or improved in 85% of 
the cases included [44]. Additionally, in a yearlong analysis comparing IVI and STI, researchers 
evaluated both modalities using CMT, BCVA, IOP, and cataract progression as parameters. A significant 
(P < 0.01) reduction in CMT for IVI groups at weeks 2, 4, 8, 12, 24 post-injection was observed when 
compared to this type of transscleral injection. Values for IVI and STI were then independently 
compared to baseline evaluations, and only IVI presented significant reduction in CMT from baseline, 
while changes seen after STI were not found to be significant at any time point. This same analysis 
showed significant (P < 0.01) logMAR BCVA improvements in the IVI group versus those in the STI 
group, and when individually compared to baseline measurements, STI of corticosteroids failed to 
show significant improvement in contrast to IVI [45]. These findings were comparable to those 
reported in a similar study by Cardillo et al., which noted an elevation in IOP for both groups without 
any adverse events [46]. 
4.2. Drawbacks of STI-TA 
The risk profile associated with STI, specifically in the area of IOP elevation, seems to be less than 
that observed for IVI drug delivery. In previous studies, IOP elevation following IV-TA treatment has 
been reported in roughly 20% to 80% of patients [37,47,48]. The aforementioned study by Inatani et al. 
examined the various risk factors for IOP elevation following STI-TA injection. The authors identified 
statistically significant risk factors for IOP elevation after STI-TA to be younger age, higher dose 
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administration and higher baseline IOP (P = 0.003, P = 0.0006, P = 0.0003 respectively) [42].  
Muller et al. employed sub-Tenon’s injections with five-eighths inch, 25-gauge needle, rather than the 
more commonly used blunt cannula, and reported that the sub-Tenon’s injection modality of corticosteroid 
delivery, even with various different steroid medications administered, seemed to be less disposed to 
produce significant intraocular hypertension [49]. Another study by Cardillo et al., elicited no increase 
in IOP to >25 mmHg treatment of DME with STI-TA [46]. Although the exact mechanism behind IOP 
elevation following ocular corticosteroid administration is not completely appreciated, it is thought to 
be derived from an increased resistance to aqueous humor outflow within the eye, and understanding 
the reason behind such a disparity between IVI and STI of corticosteroids regarding IOP elevation may 
be significant for comprehending their differences in efficacy. With regards to cataract progression 
Bonini-Fihlo et al. report no incidence of cataract progression within their study population. However, 
the authors do discuss the need for further evaluation and follow up as the limited time period of this 
study may not show progression. One must also consider that STI is an inherently more difficult procedure 
to perform. Shimura et al. investigated the effects of drug reflux (back flow of TA through the  
sub-tenon’s incision) on foveal thickness (FT) and elevations of IOP in patients with DME with a foveal 
thickness > 400 µm and a VA less than logMAR 0.3. Out of 128 patients in the study, 10 experienced 
drug reflux. Comparing the drug reflux positive group with the reflux negative group, FT was higher at 
all time points for the reflux (+) group (P = 0.004). In addition the authors noted a increase in IOP to  
>25 mmHg in 4 out of 10 eyes in the reflux (+) group in comparison to 3 out of 188 eyes in the reflux 
(-) group [50]. See Table 1 for a summary of the advantages and disadvantages of IVI and STI. 
Figure 1. Diagram illustrating the two discussed routes of triamcinolone acetonide (TA) 
administration, sub-Tenon’s infusion (STI) and intravitreal injection (IVI). STI placement 
is between Tenon’s capsule and the sclerotic coat of the eye. This is accomplished by 
making a small incision and placing a blunt curved cannula towards the posterior pole of 
the eye and infusing slowly. IVI is placed 3 to 4 mm posterior to the limbus and in the 
inferotemporal region.  
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Table 1. Advantages and disadvantages of IVI and STI use. 
IVI STI 
Pro Cons Pro Cons 
Effectively reduces 
macular thickness 
and improves BCVA 
Faster development 
of cataracts 
Small improvement in BCVA 
and macular thickness 
Technically more difficult to 
perform Correctly (i.e., risk of 
reflux) 
Increased drug 
bioavailability 
Increased risk of 
endophthalmitis 
Less risk of cataract 
development 
Many barriers that ultimately 
reduce drug bioavailablity 
 
Increased risk of 
elevated IOP and 
secondary glaucoma 
Less risk of secondary 
intraocular hypertension  
(if no reflux during procedure) 
 
5. Conclusions  
ME can develop as a result of a variety of ocular and systemic conditions including diabetes, retinal 
vein occlusion, and uveitis. The management of ME is varied and largely dictated by its etiology; 
however, given their potent anti-inflammatory properties, the use of corticosteroids has been exceedingly 
popular in treating this process, especially when administered intraocularly. We reviewed the two most 
widely studied forms of intraocular steroid delivery—intravitreal injection and sub-Tenon’s infusion. 
Currently, there seems to be a preference in treatment of ME with IVI over STI as literature suggests 
significant improvement in BCVA and reduction in CMT has been demonstrated in patients treated 
with IVI, whereas such improvements have not typically been seen with STI. Based on these findings, 
it is assumed that direct injection of corticosteroids into the vitreous allows for more effective and 
sustained release of the drug to the posterior segment of the eye than that which can be achieved when 
corticosteroids are infused beneath Tenon’s capsule; this difference in efficacy has been attributed to 
the various barriers (static, dynamic, metabolic) that exist between the sclera and posterior pole and are 
encountered by a drug that is administered via STI. Given the implications of these barriers in the 
management and outcome of treatment, modification of the corticosteroid delivery vessel may offer 
some potential for increasing the effectiveness of STI. Indeed, the efforts of Boddu et al. have recently 
investigated the use of nanoparticulate gel formation for the delivery of steroids via a transscleral 
approach [51]; however, though this research appears promising, it may be some time before clinicians 
witness this preparation in human clinical trials.  
A specific focus on the efficacy and safety of triamcinalone-acetonide (TA) was also included in 
this review, as it is the most commonly used intraocular steroid in the treatment of ME, and several 
studies report benefit from treatment with this corticosteroid. In the current literature, IV-TA has been 
associated with a statistically significant improvement in BCVA as well as a significant reduction in 
macular thickness. However, there also seems to be an increased risk for developing endophthalmitis 
with the use of IV-TA, which emphasizes the importance of using proper aseptic technique to reduce 
the likelihood of this event. Also, as with use of any intraocular steroid, an increased risk of developing 
elevated IOP, secondary glaucoma, and cataracts has been documented with use of IV-TA, and it is 
important to note that STI of TA seems to carry a lower risk for the development of ocular hypertension. 
As ocular barriers are known to hinder drug efficacy, they may also play a role in this observation by 
limiting the adverse effects of intraocular steroid treatment.  
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We can conclude that certain aspects of IV-TA and STI-TA treatment still need to be explored more 
thoroughly in order to optimize the management of ME. For instance, one issue that needs further 
clarification is that of ideal steroid dosage. Many studies have evaluated treatment with a 4 mg dose of 
TA, while others have even assessed the use of both higher and lower doses of TA. A comprehensive, 
retrospective meta-analysis comparing these outcomes may elucidate the most efficacious corticosteroid 
dosage for treating ME. Further research investigating barriers to drug delivery is also needed.  
A comprehensive understanding of the pharmacokinetics attributed by each barrier could increase drug 
bioavailability and ultimately improve treatment outcomes. Also, the applications of IV-TA and  
STI-TA use in combination with other treatment modalities such as photodynamic therapy, as well as 
the possible combination of these two injection techniques used in tandem with different therapeutic 
agents (i.e., anti VEGF factors and TA), will be of further interest regarding the future treatment of ME 
as well as in the management of other intraocular inflammatory processes.  
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